EICHOR About Solutions

Recruiting studies: Precursor B Cell Lymphoblastic Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081 Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Phase N/A · 7 location(s) · Novartis Pharmaceuticals · NCT05541341 A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528 Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770 Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06387121 Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801 CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leuk
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT06777979 Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244 CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transp
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07257419 Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem C
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07003737 Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
NA · 1 location(s) · Beijing GoBroad Hospital · NCT06343090 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT01890486 Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07584889 HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignanci
Phase 1/Phase 2 · 36 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05658640 Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06880913 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01087333 UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05535855 "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Phase N/A · 3 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06919393 Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241 A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
EARLY_Phase 1 · 1 location(s) · He Huang · NCT04227015 Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
Phase N/A · 1 location(s) · Washington University School of Medicine · NCT07313592 Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02877303 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Ly
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03136146 MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Phase 2 · 1 location(s) · Chen Suning · NCT06250959 Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194 Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05805605 CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
NA · 1 location(s) · Children's Hospital of Philadelphia · NCT03810196 CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Rel
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT07328503

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →